SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates
SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
SpringWorks Therapeutics price target lowered to $77 from $78 at Guggenheim
Guggenheim lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $77 from $78 and keeps a Buy rating on the shares. The firm is ...
3SWTX : What the Options Market Tells Us About SpringWorks Therapeutics
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $40.0 and $60.0 for SpringWorks Therapeutics, spanning the last ...